EP2373365B1 - Alignment of a needle in an intradermal injection device - Google Patents
Alignment of a needle in an intradermal injection device Download PDFInfo
- Publication number
- EP2373365B1 EP2373365B1 EP09771818.3A EP09771818A EP2373365B1 EP 2373365 B1 EP2373365 B1 EP 2373365B1 EP 09771818 A EP09771818 A EP 09771818A EP 2373365 B1 EP2373365 B1 EP 2373365B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- syringe
- contacting surface
- skin contacting
- primary skin
- needle cannula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002347 injection Methods 0.000 title claims description 33
- 239000007924 injection Substances 0.000 title claims description 33
- 210000003491 skin Anatomy 0.000 description 57
- 238000000034 method Methods 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 8
- 210000004207 dermis Anatomy 0.000 description 7
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000035515 penetration Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 238000001746 injection moulding Methods 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3287—Accessories for bringing the needle into the body; Automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
- A61M5/321—Means for protection against accidental injuries by used needles
- A61M5/3216—Caps placed transversally onto the needle, e.g. pivotally attached to the needle base
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/46—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for controlling depth of insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/42—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for desensitising skin, for protruding skin to facilitate piercing, or for locating point where body is to be pierced
- A61M5/425—Protruding skin to facilitate piercing, e.g. vacuum cylinders, vein immobilising means
Definitions
- the invention relates to devices for delivery of intradermal injections generally, and more particularly to an adapter device combinable with a standard syringe to form an assembly for delivery of an intradermal injection.
- Intradermal injections are used for delivering a variety of diagnostic and treatment compositions into a patient. Substances may be injected intradermally for diagnostic testing, such as to determine a patient's immunity status against tuberculosis and the status of allergic diseases. Vaccines, drugs and other compounds may also be delivered intradermally. In many instances, intradermal delivery is preferred because it generally requires a smaller volume dose of the diagnostic or treatment compound than other delivery techniques.
- An intradermal injection is made by delivering the substance into the epidermis and upper layer of the dermis. There is considerable variation in the skin thickness, both between individuals and within the same individual at different sites of the body. Generally the outer skin layer, or the epidermis, has a thickness between 500-200 microns and the dermis, the inner and thicker layer of the skin, has a thickness between 1.5-3.5 mm.
- Intradermal injections is difficult and generally requires an experienced nurse or medical professional. Incorrect placement of the tip of the needle cannula leads to a failed injection. The placement of the needle tip deeper than about 3.0 mm has the potential of delivering the injection into the subcutaneous region, where the intradermal dosage may be insufficient. Incorrect placement of the needle cannula may also puncture the skin again after being inserted into dermis, with the delivered compound being lost on the surface of the skin. Injection is often followed by a jet effect, with the compound exiting the injection site through the needle puncture track. The jet effect is even more pronounced for injections through a needle placed perpendicular to the injection site and in particular for shallow delivery. The success of intradermal injections is often determined by the experience of the healthcare professional.
- the preferred intradermal injection technique requires the healthcare professional to stretch the skin, orient the needle bevel to face upward, and insert a short bevel needle cannula at an angle of around 10-15 degrees, assuring that 2 to 3 mm of the needle cannula are located in the skin.
- the needle tip ends up positioned in the dermis or close to epidermis boundary.
- the compound is slowly injected into the skin of the patient, forming a blister or wheal.
- the insertion of the needle at an incorrect angle and/or depth results in a failed intradermal injection.
- Intradermal (ID) injection has been considered for immunization in the past, but has generally been rejected in favor of more reliable intramuscular or subcutaneous routes of administration because of the difficulty in making a successful ID injection.
- Mantoux tuberculin test in which a purified protein derivative is injected at a shallow angle to the skin surface using a 27 or 30 gauge needle and a standard syringe.
- the technique is known to be quite difficult to perform and requires specialized training. A degree of imprecision in the placement of the injection results in a significant number of false negative test results.
- the Mantoux approach has not led to the use of intradermal injection for systemic administration of substances, despite the advantage of requiring smaller doses of substances.
- Alchas et al. developed a unique intradermal needle assembly for the delivery of compounds into the intradermal space by penetrating the dermis perpendicularly to its surface.
- a limiter supporting the needle is placed on the skin, the needle inserted, and the compound delivered.
- the penetration depth is in the 0.5 to 3 mm range, with a device limiter setting the penetration depth.
- U.S. Patent Numbers 6,494,865 , 6,569,123 , 6,689,118 , 6,776,776 , and U.S. Patent Publication Number 2003/0199822 describe such systems.
- WIPO Patent Application Publication WO/2008/131440 discloses devices and methods for intradermal administration of diagnostic and therapeutic agents, vaccines and other compounds into the dermal layer of the skin.
- the devices and the methods simplify the ID injection process and increase the consistency of the placement of the needle tip in the dermal space close to the skin surface allowing for a shallow cannula placement in the dermis.
- the devices and methods broaden the number of sites suitable for ID injection and make successful ID injections possible with limited training.
- the syringe is loaded from the rear and slides longitudinally into the adapter.
- the invention is an adapter device for use in combination with a syringe to form an assembly for delivering an intradermal injection.
- the adapter device comprises a body which is connectable to the syringe, the body being formed at least in part as a C-shaped tube to provide an opening for receiving at least a portion of a barrel of the syringe.
- At least one support element is connected to the body. With the assembly in an assembled condition, the at least one support element supports a needle cannula connected to the syringe. The needle cannula is supported by the at least one support element intermediate a base and a tip of the needle cannula. At least a terminal portion of the needle cannula extends axially in a direction at least substantially parallel to at least a planar portion of the second primary skin contacting surface.
- the syringe 20 has a centerline.
- a needle cannula 24 is typically disposed along the centerline, but could alternatively be positioned offset from the centerline.
- the needle cannula 24 has a base 26 (see Fig. 1 ). at which the needle cannula joins a supporting hub.
- the needle cannula 24 a terminal portion 27 of the needle cannula, including a tip 28 (see Fig. 1 ), is inserted into a patient receiving the intradermal injection.
- the body 210 may be sized and shaped to accept any type of syringe 20, for example a fixed needle style syringe 30 shown in FIG. 1 , or a Luer lock style syringe (not illustrated) or other standard syringes.
- the first primary skin contacting surface 230 is preferably planar in its entirety, as illustrated, but alternatively could comprise both a planar portion and a non-planar portion (not illustrated).
- the first primary skin contacting surface 230 is optional.
- the opening 236 could be enlarged to such an extent as to effectively eliminate the first primary skin contacting surface 230. This alternative configuration is not illustrated in the drawings.
- the adapter body 210 is formed to receive the syringe 20 in a sideways motion. Stated otherwise, the body 210 includes side openings 214, including a syringe barrel side opening 216, a syringe hub portion side opening 218, and a needle cannula side opening 220.
- the syringe 20 can thus be assembled with the adapter device 200 in a direction substantially perpendicular to body centerline 212.
- the body 210 is further preferably provided with a pair of opposing finger flanges 270 to facilitate handling of the assembly during the injection process.
- First and second finger flanges 270a and 270b are configured to facilitate one-handed handling of the adapter device 200 during an injection.
- the finger flanges 270 are aligned along a central axis 272 which is at least substantially perpendicular to the planar portion of the second primary skin contacting surface 232.
- the adapter body 210 preferably comprises a single support element 240 connected to the body 210.
- the single support element 240 supports the needle cannula 24 connected to the syringe 20.
- the needle cannula 24 is supported at a point 290 positioned intermediate the needle cannula base 26 and the tip 28.
- the support element 240 functions to align the needle cannula 24 primarily relative to the second primary skin contacting surface 232 such that at least the terminal portion 27 of the needle cannula 24 extends axially in a direction substantially parallel to at least the planar portion of the second primary skin contacting surface 232.
- the single support element 240 supports the needle cannula 24 at a support point 290 which is offset from the syringe centerline in either (a) a plane substantially perpendicular to the planar portion of the second primary skin contacting surface 232 or (b) a plane substantially parallel to the planar portion of the second primary skin contacting surface.
- a first needle alignment technique is based on providing the single support element 240 having a planar portion 242.
- the planar portion 242 positions the needle cannula 24 at a known support angle 280 relative to the syringe centerline.
- the single support element 240 supports the needle cannula 24 at the support point 290 which is offset from the syringe centerline in a vertical plane 248 substantially perpendicular to the planar portion of the second primary skin contacting surface 232.
- the offset can be either toward the second primary skin contacting surface 232, or away from it (that is, either in a positive or negative y direction, (the y direction being as indicated in FIGS. 3A and 3B )).
- non-zero angle 282 is inclined in a positive y direction if the support angle 280 is similarly inclined in a positive y direction (as illustrated in FIG. 3A ), but if the support angle 280 were inclined in a negative y direction (not illustrated), the non-zero angle 282 would likewise be inclined in a negative y direction (not illustrated).
- planar support surface 242 would be positioned below the syringe centerline such that the support point 290 would fall at or outside of the cone of positional uncertainty.
- two opposing ramps 246 could be provided to "funnel" the needle cannula 24 into position along a relatively narrow planar support surface 242, or alternatively the planar support surface 242 could be sufficiently broad to ensure contact with the needle cannula 24, irrespective of the needle cannula's initial position within the cone of positional uncertainty.
- the support point 290 is offset from the syringe centerline in a horizontal plane 250 substantially parallel to the planar portion of the second primary skin contacting surface 232 (illustrated in FIG. 3A to be the x-z plane).
- the planar portion of the second primary skin contacting surface 232 is oriented substantially parallel to the syringe centerline.
- the support angle 280 is thus formed in the horizontal plane 250 that is at least substantially parallel to the second primary skin contacting surface 232.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Environmental & Geological Engineering (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Description
- The invention relates to devices for delivery of intradermal injections generally, and more particularly to an adapter device combinable with a standard syringe to form an assembly for delivery of an intradermal injection.
- Intradermal injections are used for delivering a variety of diagnostic and treatment compositions into a patient. Substances may be injected intradermally for diagnostic testing, such as to determine a patient's immunity status against tuberculosis and the status of allergic diseases. Vaccines, drugs and other compounds may also be delivered intradermally. In many instances, intradermal delivery is preferred because it generally requires a smaller volume dose of the diagnostic or treatment compound than other delivery techniques. An intradermal injection is made by delivering the substance into the epidermis and upper layer of the dermis. There is considerable variation in the skin thickness, both between individuals and within the same individual at different sites of the body. Generally the outer skin layer, or the epidermis, has a thickness between 500-200 microns and the dermis, the inner and thicker layer of the skin, has a thickness between 1.5-3.5 mm.
- Making intradermal injections is difficult and generally requires an experienced nurse or medical professional. Incorrect placement of the tip of the needle cannula leads to a failed injection. The placement of the needle tip deeper than about 3.0 mm has the potential of delivering the injection into the subcutaneous region, where the intradermal dosage may be insufficient. Incorrect placement of the needle cannula may also puncture the skin again after being inserted into dermis, with the delivered compound being lost on the surface of the skin. Injection is often followed by a jet effect, with the compound exiting the injection site through the needle puncture track. The jet effect is even more pronounced for injections through a needle placed perpendicular to the injection site and in particular for shallow delivery. The success of intradermal injections is often determined by the experience of the healthcare professional. The preferred intradermal injection technique (using a standard needle) requires the healthcare professional to stretch the skin, orient the needle bevel to face upward, and insert a short bevel needle cannula at an angle of around 10-15 degrees, assuring that 2 to 3 mm of the needle cannula are located in the skin. The needle tip ends up positioned in the dermis or close to epidermis boundary. The compound is slowly injected into the skin of the patient, forming a blister or wheal. The insertion of the needle at an incorrect angle and/or depth results in a failed intradermal injection. Intradermal (ID) injection has been considered for immunization in the past, but has generally been rejected in favor of more reliable intramuscular or subcutaneous routes of administration because of the difficulty in making a successful ID injection.
- Administration into the region of the intradermal space has been routinely used in the Mantoux tuberculin test, in which a purified protein derivative is injected at a shallow angle to the skin surface using a 27 or 30 gauge needle and a standard syringe. The technique is known to be quite difficult to perform and requires specialized training. A degree of imprecision in the placement of the injection results in a significant number of false negative test results. As a result, the Mantoux approach has not led to the use of intradermal injection for systemic administration of substances, despite the advantage of requiring smaller doses of substances.
- There have been attempts to develop devices that would assure a precise needle penetration depth during ID injection which tends to vary due to tissue compliance, penetration angle, skill level and other factors. These are detailed in
US Patent Numbers 4,393,870 and6,200,291 andUS Published Patent Applications Numbers 2003/0093032 and2004/0147901 . These devices employ complex constructions that tension the skin by vacuum, expanding the mounting surface prior to the needle insertion. - Alchas et al. developed a unique intradermal needle assembly for the delivery of compounds into the intradermal space by penetrating the dermis perpendicularly to its surface. A limiter supporting the needle is placed on the skin, the needle inserted, and the compound delivered. The penetration depth is in the 0.5 to 3 mm range, with a device limiter setting the penetration depth. There is a broad range of patents, issued and pending, defining different features of the system.
U.S. Patent Numbers 6,494,865 ,6,569,123 ,6,689,118 ,6,776,776 , andU.S. Patent Publication Number 2003/0199822 describe such systems. The main limitation of the systems developed by Alchas et al. is the broad range of deposit depth due to assembly tolerances, needle bevel and the variations in skin properties. Another concern is back flow through the needle channel from the deposit pool to the surface of the skin due to a short direct channel formed by the needle. The jet effect further limits the performance when a shallow delivery is attempted. - The lack of suitable devices to accomplish reproducible delivery to the epidermal and dermal skin layers has limited the widespread use of the ID delivery route. Using conventional devices, ID injection is difficult to perform, unreliable and painful to the subject. There is thus a need for devices and methods that will enable efficient, accurate and reproducible delivery of agents to the intradermal layer of skin.
- WIPO Patent Application Publication
WO/2008/131440 ("the '440 publication") discloses devices and methods for intradermal administration of diagnostic and therapeutic agents, vaccines and other compounds into the dermal layer of the skin. The devices and the methods simplify the ID injection process and increase the consistency of the placement of the needle tip in the dermal space close to the skin surface allowing for a shallow cannula placement in the dermis. Furthermore, the devices and methods broaden the number of sites suitable for ID injection and make successful ID injections possible with limited training. However, the syringe is loaded from the rear and slides longitudinally into the adapter. - The applicability of devices disclosed in the '440 publication would be substantially broadened with design improvements allowing for improved placement depth of the cannula in the dermis. Furthermore, a design facilitating the ease of device and syringe merger would be of a substantial benefit. The improvements facilitating the ID injection using one hand and other features would also be beneficial for the use of ID devices and methods. There is thus a need for improvements to devices and methods for efficient accurate and reproducible delivery of agents to the intradermal layer of skin.
- Briefly stated, in a first aspect the invention is an adapter device for use in combination with a syringe to form an assembly for delivering an intradermal injection. The adapter device comprises a body which is connectable to the syringe, the body being formed at least in part as a C-shaped tube to provide an opening for receiving at least a portion of a barrel of the syringe. At least one support element is connected to the body. With the assembly in an assembled condition, the at least one support element supports a needle cannula connected to the syringe. The needle cannula is supported by the at least one support element intermediate a base and a tip of the needle cannula. At least a terminal portion of the needle cannula extends axially in a direction at least substantially parallel to at least a planar portion of the second primary skin contacting surface.
- Preferably, the adapter device further comprises a first primary skin contacting surface positioned at the distal end of the body. The first primary skin contacting surface is positioned at an angle to the second primary skin contacting surface between approximately 100 degrees and approximately 165 degrees.
- The adapter device may preferably include a single support element connected to the body, wherein the support element supports the needle cannula at a point offset from a syringe centerline in one of a plane at least substantially perpendicular to the planar portion of the second primary skin contacting surface or a plane at least substantially parallel to the planar portion of the second primary skin contacting surface.
- The foregoing summary, as well as the following detailed description of the invention, will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, there are shown in the drawings embodiments which are presently preferred. It should be understood, however, that the invention is not limited to the precise arrangements and instrumentalities shown.
- In the drawings:
-
FIG. 1 is a side elevational view of an adapter device in accordance with a second preferred embodiment of the present invention, shown with a fixed needle syringe in axial alignment in preparation for assembly with the adapter device; -
FIG. 2 is a rear perspective view of the adapter device and syringe ofFIG. 1 , shown in an assembled condition; -
FIG. 3A is a schematic representation of a side view of a first needle alignment technique, capable of being incorporated into the adapter device ofFIG. 1 ; -
FIG. 3B is a schematic representation of an end view of the needle alignment technique ofFIG. 3A ; -
FIG. 4A is a schematic representation of a top plan view of a second needle alignment technique, capable of being incorporated into the adapter device ofFIG. 1 ; and -
FIG. 4B is a schematic representation of an end view of the needle alignment technique ofFIG. 4A . - Certain terminology is used in the following description for convenience only and is not limiting. The words "right", "left", "lower", "upper", "horizontal" and "vertical" designate directions in the drawings to which reference is made. The words "inwardly" and "outwardly" refer to directions toward and away from, respectively, the geometric center of the adapter device.
- With reference now to
FIG. 1 , a presently preferred embodiment adapter device 200 is, intended for use in combination with asyringe 20 to form an assembly 10 for delivering an intradermal injection. The adapter device 200 comprises a body 210 connectable to thesyringe 20. The body 210 is preferably formed in one piece as an integral, unitary component. The body 210 is preferably formed using conventional polymeric materials, such as polypropylene, using conventional fabrication techniques, for example, injection molding. Other known conventional materials and fabrication techniques could also be used. - The embodiment body 210 may be sized and shaped to accept any type of
syringe 20, for example a fixed needle style syringe 30 shown inFIG. 1 , or a Luer lock style syringe (not illustrated) or other standard syringes. - The
syringe 20 has a centerline. Aneedle cannula 24 is typically disposed along the centerline, but could alternatively be positioned offset from the centerline. At a first, proximal end, theneedle cannula 24 has a base 26 (seeFig. 1 ). at which the needle cannula joins a supporting hub. At a second, distal end, the needle cannula 24 aterminal portion 27 of the needle cannula, including a tip 28 (seeFig. 1 ), is inserted into a patient receiving the intradermal injection. - With reference now to
FIG. 1 , a presently preferred embodiment adapter device 200 is intended for use in combination with asyringe 20 to form an assembly 10 for delivering an intradermal injection. The adapter device 200 comprises a body 210 connectable to thesyringe 20. The body 210 is preferably formed in one piece as an integral, unitary component. The body 210 is preferably formed using conventional polymeric materials, such as polypropylene, using conventional fabrication techniques, for example, injection molding. Other known conventional materials and fabrication techniques could also be used. - The body 210 may be sized and shaped to accept any type of
syringe 20, for example a fixed needle style syringe 30 shown inFIG. 1 , or a Luer lock style syringe (not illustrated) or other standard syringes. - The body 210 has a
body centerline 212, which, in the assembled condition, is preferably, but not necessarily, coincident with the syringe centerline. The body further comprises a second primaryskin contacting surface 232 positioned at adistal end 226 of the body 210. The second primaryskin contacting surface 232 is preferably, as illustrated, in its entirety a planar surface. Alternatively, the second primaryskin contacting surface 232 could comprise both a planar surface forming only a portion of the second primaryskin contacting surface 232, with a remaining portion of the second skin contacting surface being non-planar. In one embodiment, as illustrated inFIG. 1 , the second primaryskin contacting surface 232 is at least generally parallel to the syringe centerline andadapter body centerline 212. As discussed below relative to a second alignment technique illustrated inFIGS. 3A and 3B , at least the planar portion of the second primaryskin contacting surface 232 could be inclined either up or down relative to the syringe andbody centerlines 212. - Preferably, the second embodiment adapter body 210 further comprises a first primary
skin contacting surface 230 positioned at thedistal end 226 of the body 210. Preferably the first and second primaryskin contacting surfaces FIG. 3A ) between approximately 100 degrees and approximately 165 degrees. The first primaryskin contacting surface 230 includes an opening 236 (illustrated only schematically inFIG. 3A ) through which theneedle cannula 24 extends through the first primaryskin contacting surface 230. Note that theopening 236 must be sized sufficiently large to accommodate deflection of the needle illustrated schematically inFIGS. 3A and4A . - Like the second primary
skin contacting surface 232, the first primaryskin contacting surface 230 is preferably planar in its entirety, as illustrated, but alternatively could comprise both a planar portion and a non-planar portion (not illustrated). - Note as before with the first embodiment adapter device 100, that the first primary
skin contacting surface 230 is optional. Alternatively, theopening 236 could be enlarged to such an extent as to effectively eliminate the first primaryskin contacting surface 230. This alternative configuration is not illustrated in the drawings. - The adapter body 210 is formed to receive the
syringe 20 in a sideways motion. Stated otherwise, the body 210 includesside openings 214, including a syringe barrel side opening 216, a syringe hubportion side opening 218, and a needlecannula side opening 220. Thesyringe 20 can thus be assembled with the adapter device 200 in a direction substantially perpendicular tobody centerline 212. - With reference now to both
FIG. 1 andFIG. 2 , the adapter body 210, is formed at least in part as a C-shapedtube 222 having grippingtabs 224. As best seen inFIG. 2 , thegripping tabs 224 retain thesyringe barrel 32 within the C-shapedtube 222. As the artisan skilled in the art of injection molding will appreciate, to facilitate the molding fabrication process,openings 225 are preferably provided to allow opposing molds to form the body 210, including thegripping tabs 224. - With continued reference to
FIG. 1 , the body 210 is further preferably provided with a pair of opposingfinger flanges 270 to facilitate handling of the assembly during the injection process. First andsecond finger flanges finger flanges 270 are aligned along acentral axis 272 which is at least substantially perpendicular to the planar portion of the second primaryskin contacting surface 232. - Before proceeding further with the detailed description of the invention, it should be noted relative to the schematic representations of needle alignment techniques to be discussed herein below that the simple linear deflected shapes schematically illustrated do not accurately reflect the actual deflected shape of the
needle cannula 24, which of course will vary depending on the support conditions and flexure characteristics of the actual needle cannula 24 (for example, stiffness of the needle hub, material of theneedle cannula 24, and diameter of the needle cannula 24). Accordingly, the simplified linear shapes shown should be understood to be mere approximations. - With reference now to
FIGS. 2A and 2B , the adapter body 210 preferably comprises a single support element 240 connected to the body 210. With the assembly in an assembled condition, the single support element 240 supports theneedle cannula 24 connected to thesyringe 20. Theneedle cannula 24 is supported at apoint 290 positioned intermediate theneedle cannula base 26 and thetip 28. The support element 240 functions to align theneedle cannula 24 primarily relative to the second primaryskin contacting surface 232 such that at least theterminal portion 27 of theneedle cannula 24 extends axially in a direction substantially parallel to at least the planar portion of the second primaryskin contacting surface 232. In general, the single support element 240 supports theneedle cannula 24 at asupport point 290 which is offset from the syringe centerline in either (a) a plane substantially perpendicular to the planar portion of the second primaryskin contacting surface 232 or (b) a plane substantially parallel to the planar portion of the second primary skin contacting surface. - More particularly, as illustrated schematically in
FIGS. 2A and 2B , a first needle alignment technique is based on providing the single support element 240 having a planar portion 242. With thesyringe 20 and second embodiment adapter device 200 fully assembled, the planar portion 242 positions theneedle cannula 24 at a knownsupport angle 280 relative to the syringe centerline. More particularly, the single support element 240 supports theneedle cannula 24 at thesupport point 290 which is offset from the syringe centerline in avertical plane 248 substantially perpendicular to the planar portion of the second primaryskin contacting surface 232. The offset can be either toward the second primaryskin contacting surface 232, or away from it (that is, either in a positive or negative y direction, (the y direction being as indicated inFIGS. 3A and 3B )). - In order to appropriately control the depth of the injection, the planar portion of the second primary
skin contacting surface 232 is inclined relative to the syringe centerline at a non-zero angle 282 (nominally equal to angle 280), such that the planar portion of the second primaryskin contacting surface 232 is oriented substantially parallel to theterminal portion 27 of the needle cannula proximate thetip 28. Thesupport angle 280 and thenon-zero angle 282 are thus formed in the vertical plane 248 (illustrated inFIGS. 3A and 3B as the x-y plane) that is at least substantially perpendicular to the second primaryskin contacting surface 232. Note that thenon-zero angle 282 is inclined in a positive y direction if thesupport angle 280 is similarly inclined in a positive y direction (as illustrated inFIG. 3A ), but if thesupport angle 280 were inclined in a negative y direction (not illustrated), thenon-zero angle 282 would likewise be inclined in a negative y direction (not illustrated). - Recall that the simple linear deflected shape schematically illustrated does not accurately reflect the actual deflected shape of the needle. Accordingly, the actual optimal angle at which the second primary skin contacting surface should be inclined to the syringe centerline to accomplish as nearly as possible parallelism between the
terminal portion 27 of the needle and the planar portion of the second primaryskin contacting surface 232 may not beangle 280, but rather an angle approximately equal to supportangle 280. In practice, thenon-zero angle 282 may exceed thesupport angle 280 due to the fact that theneedle cannula 24 will leave the hub along the syringe centerline and then be deflected atsupport point 290. - With reference to
FIG. 3B , theneedle cannula 24 is captured first by aramp portion 246 which guides theneedle cannula 24 to the planar portion 242 during the process of assembling thesyringe 20 with the adapter device 200. A ramp design is needed in view of the uncertainty of where theneedle cannula 24 is initially positioned. Theramp 246 extends sufficiently far from the syringe centerline such that the cone of uncertainty of where theneedle cannula 24 is initially positioned is captured within theramp portion 246. Note that theramp portion 246 must terminate, and the planar portion 242 begin at a point at or beyond the cone of positional uncertainty such that when theneedle cannula 24 is in its final supported position, thesupport point 290 falls along the planar portion 242. - Note that
FIG. 3B illustrates assembly of thesyringe 20 with the adapter 200 in a direction along the z axis (that is, "side insertion" along the horizontal axis). This same first alignment technique could be applied to an adapter (not illustrated) which receives the syringe in a direction along the y axis (that is, "bottom insertion" along the vertical axis). Theneedle cannula 24 will be deflected in a manner substantially similar to that illustrated inFIG. 3A , but in a negative y direction rather than a positive y direct. The planar portion of the second primaryskin contacting surface 232 would likewise be inclined in a negative y direction. The planar support surface 242 would be positioned below the syringe centerline such that thesupport point 290 would fall at or outside of the cone of positional uncertainty. In this embodiment (not illustrated), two opposingramps 246 could be provided to "funnel" theneedle cannula 24 into position along a relatively narrow planar support surface 242, or alternatively the planar support surface 242 could be sufficiently broad to ensure contact with theneedle cannula 24, irrespective of the needle cannula's initial position within the cone of positional uncertainty. - With reference now to
FIGS. 4A and 4B , in a second needle cannula alignment technique, thesupport point 290 is offset from the syringe centerline in ahorizontal plane 250 substantially parallel to the planar portion of the second primary skin contacting surface 232 (illustrated inFIG. 3A to be the x-z plane). In contrast to the first alignment technique, in the second alignment technique the planar portion of the second primaryskin contacting surface 232 is oriented substantially parallel to the syringe centerline. In this second alignment technique, thesupport angle 280 is thus formed in thehorizontal plane 250 that is at least substantially parallel to the second primaryskin contacting surface 232.FIG. 4B illustrates that a single support element 240 having a V-groove portion 244 is used with this second needle cannula alignment technique. Similar to the concept behind sizing of theramp portion 246 of the first alignment technique, the V-groove portion 244 is sized to capture theneedle cannula 24 no matter where it is located within the cone of positional uncertainty associated with the expected range of angular straightness tolerance of theneedle cannula 24. - As with the first alignment technique, it would be possible to reorient the V-groove portion 244 from a side insertion configuration (illustrated in
FIGS. 4A and 4B ) to a bottom insertion configuration (not illustrated), wherein the V-groove portion 244 is rotated 90 degrees, and the offset occurs in thevertical plane 248, which is at least substantially perpendicular to thehorizontal plane 250. With such a reorientation, it would of course be necessary to also modify the orientation of the planar portion of the second primaryskin contacting surface 232 relative to the syringe centerline such that the terminal portion of theneedle cannula 24 is substantially parallel to the planar portion of the second primaryskin contacting surface 232 in the assembled condition. - Rather than incorporating the V-groove portion 244 illustrated, alternatively two opposing inclined ramp portions (corresponding to opposing sides of the V-groove portion 244) could be provided, but rather than joining together at the vertex, the opposing sides could join opposing sides of a slot (not illustrated). The width of the slot could be slightly larger than the diameter of the
needle cannula 24, to allow theneedle cannula 24 to slide within the slot (not illustrated). The closed end of the slot would be positioned along the syringe centerline. Thus, the slot (not illustrated) would extend from approximately from where the vertex of the V-groove portion 244 would fall in the illustrated embodiment (seeFIG. 4B ) to the syringe centerline. Depending upon its initial position within the cone of positional uncertainty, theneedle cannula 24 would be positioned at some point within the slot after assembly of thesyringe 20 with the adapter device 200. - It will be appreciated by those skilled in the art that changes could be made to the embodiments described above without departing from the broad inventive concept thereof. It is understood, therefore, that this invention is not limited to the particular embodiments disclosed, but it is intended to cover modifications within the scope of the present invention as defined by the appended claims.
Claims (11)
- An adapter device (200) connectable to a syringe (20) to form an assembly for delivering an intradermal injection, comprising:a body (210) connectable to the syringe, the body (210) is formed at least in part as a C-shaped tube (222) to provide an opening (216) for receiving at least a portion of a barrel (32) of the syringe:a second primary skin contacting surface (232) positioned at a distal end (226) of the body; andat least one support element (240) connected to the body, wherein:with the assembly in an assembled condition:the at least one support element supports a needle cannula (24) connected to the syringe, with the needle cannula supported by the at least one support element intermediate a base (26) and a tip (28) of the needle cannula, andat least a terminal portion (27) of the needle cannula proximate the tip extends axially in a direction at least substantially parallel to at least a planar portion of the second primary skin contacting surface (232).
- The adapter device of claim 1, further comprising a first primary skin contacting surface (230) positioned at the distal end of the body and further positioned at an angle (234) to the second primary skin contacting surface (232) between approximately 100 degrees and approximately 154 degrees.
- The adapter device of claim 1, wherein the syringe is a fixed needle style syringe (30).
- The adapter device of claim 1, wherein the syringe is a Luer lock style syringe.
- The adapter device of claim 1, further comprising a pair of finger flanges (270) connected to the body (210) wherein the finger flanges are aligned along a central axis (27) that is at least substantially perpendicular to a plane containing at least the planar portion of the second primary skin contacting surface (232).
- The adapter device of claim 1, wherein:a single support element (240) is connected to the body, andthe single support element supports the needle cannula (24) at a point (290) offset from a syringe centerline (22) in one of a plane (248) at least substantially perpendicular to the planar portion of the second primary skin contacting surface or a plane (250) at least substantially parallel to the planar apportion of the second primary skin contracting surface (232).
- The adapter device of claim 6, wherein the point offset from the syringe (20) centerline is in the plane substantially perpendicular to the planar portion of the second primary skin contacting surface (232), and the planar portion of the second primary skin contacting surface is inclined relative to the syringe centerline at a non-zero angle (282) such that the planar portion of the second primary skin contacting surface is oriented substantially parallel to the terminal portion (27) of the needle cannula (24) proximate the tip (28).
- The adapter device of claim 6, wherein the point offset from the syringe centerline is in the plane substantially parallel to the planar portion of the second primary skin contacting surface (232) and the planar portion of the second primary skin contacting surface is oriented substantially parallel to the syringe centerline.
- The adapter device of claim 6, wherein the non-zero angle at least equals an expected range of angular straightness tolerance of the needle cannula (24).
- The adapter device of claim 6, wherein a portion (242) of the single support element engaging the needle cannula (24) is planar and the non-zero angle is formed in the plane (248) that is at least substantially perpendicular to the second primary skin contacting surface (232).
- The adapter device of claim 6, wherein a portion (244) of the support element engaging the needle cannula (24) has a V-groove shape and the non-zero angle is formed in the plane (25) that is a least substantially parallel to the second primary skin contacting surface (232).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20112508P | 2008-12-08 | 2008-12-08 | |
US20327408P | 2008-12-22 | 2008-12-22 | |
PCT/US2009/066960 WO2010077596A1 (en) | 2008-12-08 | 2009-12-07 | Alignment of a needle in an intradermal injection device |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2373365A1 EP2373365A1 (en) | 2011-10-12 |
EP2373365B1 true EP2373365B1 (en) | 2014-04-23 |
Family
ID=41698112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09771818.3A Active EP2373365B1 (en) | 2008-12-08 | 2009-12-07 | Alignment of a needle in an intradermal injection device |
Country Status (5)
Country | Link |
---|---|
US (1) | US20110224609A1 (en) |
EP (1) | EP2373365B1 (en) |
CN (1) | CN102307612B (en) |
BR (1) | BRPI0922213B8 (en) |
WO (1) | WO2010077596A1 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5213950B2 (en) | 2007-04-23 | 2013-06-19 | エス・アイ・ディ・テクノロジーズ・リミテッド・ライアビリティ・カンパニー | Method and apparatus for intradermal injection |
EP2349415B1 (en) * | 2008-11-07 | 2020-01-01 | Becton, Dickinson and Company | Syringe housing to facilitate medication injection |
BR112012001498B8 (en) | 2009-07-23 | 2021-06-22 | Program For Appropriate Tech In Health | intradermal injection assembly |
ES2575546T3 (en) * | 2010-03-12 | 2016-06-29 | Sid Technologies Llc | Set for use with a syringe |
EP4015022A1 (en) | 2010-12-06 | 2022-06-22 | AktiVax, Inc. | Aseptic cartridge |
EP2665502B1 (en) | 2011-01-17 | 2020-03-25 | AktiVax, Inc. | Aseptic cartridge and dispenser arrangement |
EP2489379B1 (en) | 2011-01-21 | 2020-09-23 | SID Technologies, LLC | Intradermal pen adapter |
EP2701783B1 (en) * | 2011-04-28 | 2021-03-24 | Sanofi-Aventis Deutschland GmbH | Connection for medical device |
EP2703027B1 (en) * | 2011-04-28 | 2018-10-24 | Terumo Kabushiki Kaisha | Hypodermic needle assembly and drug injection device |
US8801680B2 (en) * | 2012-03-14 | 2014-08-12 | Becton, Dickinson And Company | Angled retracting sheath for safety needle |
CN105246533B (en) * | 2013-03-04 | 2018-03-23 | Sid技术有限责任公司 | Side merges intracutaneous adapter |
US9474865B2 (en) | 2013-04-25 | 2016-10-25 | West Pharmaceutical Services, Inc. | Needle shield for disposable syringe with annular ring |
WO2024112690A1 (en) * | 2022-11-21 | 2024-05-30 | Action Medical Technologies, Llc | Parenteral injection system |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2701566A (en) * | 1950-02-07 | 1955-02-08 | Becton Dickinson Co | Injection apparatus |
US3324854A (en) * | 1964-04-23 | 1967-06-13 | Harry Swartz | Apparatus for facilitating the insertion of a hypodermic syringe needle |
US4393870A (en) * | 1974-11-19 | 1983-07-19 | Wolfgang Wagner | Suction injector |
US4332248A (en) * | 1980-07-31 | 1982-06-01 | Devitis Thomas N | Medical apparatus |
GB8519049D0 (en) * | 1985-07-29 | 1985-09-04 | Bryne P O | Safety device |
US4631057A (en) | 1985-12-17 | 1986-12-23 | Dolores A. Smith | Shielded needle |
US4801295A (en) | 1986-05-22 | 1989-01-31 | Spencer Treesa A | Disposable hypodermic syringe and needle combination having retractable, accident preventing sheath |
US4737144A (en) * | 1987-03-09 | 1988-04-12 | Choksi Pradip V | Syringe with selectively exposed and enveloped needle |
US4747837A (en) * | 1987-05-01 | 1988-05-31 | Hauck Martin W | Syringe needle recapping protective device |
US4850996A (en) * | 1988-02-22 | 1989-07-25 | Cree Ian C | Safety needle |
US4894054A (en) * | 1988-06-20 | 1990-01-16 | Miskinyar Shir A | Preloaded automatic disposable syringe |
US5053018A (en) | 1988-06-28 | 1991-10-01 | Sherwood Medical Company | Combined syringe and needle shield and method of manufacture |
US4958625A (en) * | 1989-07-18 | 1990-09-25 | Boston Scientific Corporation | Biopsy needle instrument |
US4998920A (en) * | 1989-10-11 | 1991-03-12 | Delores Johnson | Protective assembly for hypodermic syringe devices |
US5108378A (en) * | 1990-05-09 | 1992-04-28 | Safety Syringes, Inc. | Disposable self-shielding hypodermic syringe |
CN2117905U (en) * | 1992-01-27 | 1992-10-07 | 丛日刚 | Standard device for subcutaneous injection |
DE4205036C1 (en) * | 1992-02-19 | 1993-06-17 | Henke-Sass, Wolf Gmbh, 7200 Tuttlingen, De | Injection cylinder for subcutaneous vaccination - comprises first hollow cylindrical tube in which is fitted telescopically second tube with reduced dia. |
FR2694198B1 (en) * | 1992-07-31 | 1994-10-21 | Claude Trapp | Injection needle protection device. |
US5496288A (en) * | 1992-09-23 | 1996-03-05 | Becton, Dickinson And Company | Protective cap for hypodermic syringe |
US5437640A (en) * | 1994-01-31 | 1995-08-01 | Schwab; Louis | Apparatus and method for inserting hypodermic, tuberculin and other needles and for administering Mantoux tuberculin tests |
US5498242A (en) * | 1995-04-24 | 1996-03-12 | Cooke; Thomas H. | Medical needle sheath and stand for one-handed use |
FR2733687B1 (en) * | 1995-05-04 | 1997-10-03 | Brunel Marc | METHOD FOR MANUFACTURING A PRE-FILLED INJECTION DEVICE CONTAINING A DOSE OF LIQUID TO BE INJECTED, AND INJECTION DEVICE PRODUCED |
US5827216A (en) * | 1995-06-07 | 1998-10-27 | Cormedics Corp. | Method and apparatus for accessing the pericardial space |
US5779675A (en) * | 1995-08-25 | 1998-07-14 | Medrad, Inc. | Front load pressure jacket system with syringe holder |
US5718239A (en) * | 1996-06-21 | 1998-02-17 | Becton, Dickinson And Company | Method of activating a needle assembly having a telescoping shield |
US6117108A (en) * | 1997-08-20 | 2000-09-12 | Braun Melsungen Ag | Spring clip safety IV catheter |
IT1298087B1 (en) * | 1998-01-08 | 1999-12-20 | Fiderm S R L | DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS |
US6036675A (en) * | 1999-02-03 | 2000-03-14 | Specialized Health Products, Inc. | Safety sterile cartride unit apparatus and methods |
US20020193740A1 (en) * | 1999-10-14 | 2002-12-19 | Alchas Paul G. | Method of intradermally injecting substances |
US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
US6569123B2 (en) * | 1999-10-14 | 2003-05-27 | Becton, Dickinson And Company | Prefillable intradermal injector |
US6776776B2 (en) | 1999-10-14 | 2004-08-17 | Becton, Dickinson And Company | Prefillable intradermal delivery device |
US7241275B2 (en) | 1999-10-14 | 2007-07-10 | Becton, Dickinson And Company | Intradermal needle |
US7052483B2 (en) * | 2000-12-19 | 2006-05-30 | Animas Corporation | Transcutaneous inserter for low-profile infusion sets |
EP1381415A1 (en) * | 2001-04-13 | 2004-01-21 | Becton, Dickinson and Company | Method of intradermally injecting substances |
US6582397B2 (en) * | 2001-06-19 | 2003-06-24 | Portex, Inc. | Needle safety device with antiremoval protection |
US8048097B2 (en) * | 2001-08-14 | 2011-11-01 | Steven Schraga | Single use lancet assembly |
CA2460063C (en) * | 2001-09-12 | 2010-07-20 | Becton, Dickinson And Company | Microneedle-based pen device for drug delivery and method for using same |
AU2002346399A1 (en) * | 2001-11-14 | 2003-05-26 | Medical Instill Technologies, Inc. | Intradermal delivery device and method |
AU2003253859A1 (en) * | 2002-07-08 | 2004-01-23 | Medical Instill Technologies, Inc. | Interadermal delivery device, and method of intradermal delivery |
EP1944051A4 (en) * | 2005-10-31 | 2009-09-02 | Terumo Corp | Puncture device, dosing device and puncture method |
US7842008B2 (en) * | 2005-11-21 | 2010-11-30 | Becton, Dickinson And Company | Intradermal delivery device |
JP4828283B2 (en) * | 2006-03-30 | 2011-11-30 | テルモ株式会社 | Needleless injection device |
JP5213950B2 (en) * | 2007-04-23 | 2013-06-19 | エス・アイ・ディ・テクノロジーズ・リミテッド・ライアビリティ・カンパニー | Method and apparatus for intradermal injection |
US20090270806A1 (en) * | 2008-04-24 | 2009-10-29 | Medtronic Vascular, Inc. | Devices and Methods for Controlled-Depth Injection |
US20110238038A1 (en) * | 2008-12-04 | 2011-09-29 | Nanopass Technologies Ltd. | Intradermal mini - needle interface and associated devices and methods |
-
2009
- 2009-12-07 CN CN200980148920.5A patent/CN102307612B/en active Active
- 2009-12-07 US US13/057,006 patent/US20110224609A1/en not_active Abandoned
- 2009-12-07 BR BRPI0922213A patent/BRPI0922213B8/en active IP Right Grant
- 2009-12-07 EP EP09771818.3A patent/EP2373365B1/en active Active
- 2009-12-07 WO PCT/US2009/066960 patent/WO2010077596A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CN102307612A (en) | 2012-01-04 |
BRPI0922213B8 (en) | 2021-06-22 |
EP2373365A1 (en) | 2011-10-12 |
BRPI0922213A2 (en) | 2018-05-22 |
US20110224609A1 (en) | 2011-09-15 |
CN102307612B (en) | 2015-01-07 |
WO2010077596A1 (en) | 2010-07-08 |
BRPI0922213B1 (en) | 2020-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2373365B1 (en) | Alignment of a needle in an intradermal injection device | |
US9089655B2 (en) | Intradermal injection adapter | |
EP2139543B1 (en) | Devices for intradermal injection | |
EP2007455B1 (en) | Improvements relating to the insertion of a medical needle | |
EP3359222B1 (en) | Patch injector with slidable joint | |
JP5030963B2 (en) | Disposable needle and hub assembly | |
EP2531242B1 (en) | Dermal access device | |
US20090247953A1 (en) | Microneedle adaptor for dosed drug delivery devices | |
MXPA06010227A (en) | Intradermal syringe and needle assembly. | |
WO2008139303A2 (en) | A novel device for intradermal injection | |
US8876764B2 (en) | Intradermal pen adapter | |
US20220176045A1 (en) | Injection assembly with movable sleeve | |
US20150038911A1 (en) | Microneedle adapter for dosed drug delivery devices | |
JP7459062B2 (en) | Syringe assembly and adapter parts | |
JP7503699B2 (en) | Needle |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20110519 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20121009 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20131202 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 663414 Country of ref document: AT Kind code of ref document: T Effective date: 20140515 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602009023513 Country of ref document: DE Effective date: 20140528 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 663414 Country of ref document: AT Kind code of ref document: T Effective date: 20140423 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20140423 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140724 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140723 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140723 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140823 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140825 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602009023513 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 |
|
26N | No opposition filed |
Effective date: 20150126 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602009023513 Country of ref document: DE Effective date: 20150126 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141207 Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20141207 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141231 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141207 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141231 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141207 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20091207 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140423 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20231227 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20231229 Year of fee payment: 15 |